SCHEMBL14919637

SCHEMBL14919637

Nc1cccc(C(F)(F)F)c1Br

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS2R14 Q9NYV8 1/20 0.40
POLB P06746 3/20 0.38
TDP1 Q9NUW8 3/20 0.38
ALDH1A1 P00352 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
HTR2C P28335 2/20 0.36
P2RX7 Q99572 1/20 0.36
TSHR P16473 3/20 0.35
GAA P10253 3/20 0.35
GLA P06280 1/20 0.35
MAPK1 P28482 1/20 0.35
IDO1 P14902 2/20 0.35
MPL P40238 1/20 0.35
CUL4A Q13619 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
CYP3A4 P08684 1/20 0.35
HPGD P15428 1/20 0.35
HSD17B10 Q99714 1/20 0.35
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL11741355 0.98 POLB (0.41) TAS2R14POLBTDP1ALDH1A1L3MBTL1
SCHEMBL1041748 0.83 TAS2R14 (0.46) TAS2R14POLBTDP1ALDH1A1L3MBTL1
SCHEMBL15950944 0.83 CYP3A4 (0.36) TDP1ALDH1A1P2RX7TSHRSMN1; SMN2
SCHEMBL9812334 0.77 CA2 (0.44) TDP1ALDH1A1TSHRSMN1; SMN2CYP3A4
SCHEMBL29589903 0.76 CD44 (0.42) POLBTDP1ALDH1A1L3MBTL1TSHR
SCHEMBL7191759 0.76 TAS2R14 (0.42) TAS2R14POLBTDP1ALDH1A1L3MBTL1
SCHEMBL476347 0.76 CD44 (0.42) POLBTDP1ALDH1A1L3MBTL1TSHR
SCHEMBL70554 0.75 ALDH1A1 (0.48) POLBTDP1ALDH1A1L3MBTL1HTR2C
SCHEMBL8994564 0.75 ALDH1A1 (0.48) POLBTDP1ALDH1A1L3MBTL1HTR2C
SCHEMBL29882203 0.75 ALDH1A1 (0.48) POLBTDP1ALDH1A1L3MBTL1HTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12577240-B2 Antiviral heteroaryl ketone derivatives PFIZER INC. (US) 2026-03-17 US disclosed
US-20250171420-A1 MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME MONTE ROSA THERAPEUTICS AG (CH) 2025-05-29 US disclosed
EP-4540240-A1 MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME Monte Rosa Therapeutics AG (CH) 2025-04-23 EP disclosed
EP-4217062-B1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2024-10-09 EP disclosed
US-20240208902-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2024-06-27 US disclosed
WO-2023244815-A1 MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME MONTE ROSA THERAPEUTICS, INC. (US) 2023-12-21 WO disclosed
US-11802111-B2 Cyclobutyl amide monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2023-10-31 US disclosed
US-20230339930-A1 Antiviral Heteroaryl Ketone Derivatives PFIZER INC. (US) 2023-10-26 US disclosed
US-20230339930-A1 Antiviral Heteroaryl Ketone Derivatives PFIZER INC. (US) 2023-10-26 US disclosed
US-20230339930-A1 Antiviral Heteroaryl Ketone Derivatives PFIZER INC. (US) 2023-10-26 US disclosed
US-8633182-B2 Indanyloxyphenylcyclopropanecarboxylic acids BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-01-21 US disclosed
US-8633182-B2 Indanyloxyphenylcyclopropanecarboxylic acids BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-01-21 US disclosed
WO-2013178575-A1 NEW INDANYLOXYPHENYLCYCLOPROPANECARB OXYLIC ACIDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-12-05 WO disclosed
WO-2013164292-A1 INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-11-07 WO disclosed
WO-2013164292-A1 INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-11-07 WO disclosed
US-20130289074-A1 NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-10-31 US disclosed
US-20130289074-A1 NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-10-31 US disclosed
US-20130289074-A1 NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-10-31 US disclosed
WO-2013144098-A1 NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACID DERIVATIVES AND THEIR USE AS GPR40 RECEPTOR AGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-10-03 WO disclosed
WO-2013066729-A1 AMINOPYRIMIDINONES AS INTERLEUKIN RECEPTOR-ASSOCIATED KINASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2013-05-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12577240-B2 Antiviral heteroaryl ketone derivatives ACE2, SARS1, ACE TAS2R14 3179/4885POLB 760/4885TDP1 4247/4885
US-20230339930-A1 Antiviral Heteroaryl Ketone Derivatives ACE2, ZC3HAV1, SARS1 TAS2R14 3767/4885POLB 263/4885TDP1 3680/4885
US-20240208902-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS MGLL, LPL, PNLIP TAS2R14 1994/4885POLB 846/4885TDP1 1221/4885
US-20250171420-A1 MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME PSMA1, CSNK1G1, CSNK1A1 TAS2R14 4592/4885POLB 932/4885TDP1 604/4885
US-11802111-B2 Cyclobutyl amide monoacylglycerol lipase modulators MGLL, LPL, PNLIP TAS2R14 1961/4885POLB 841/4885TDP1 1190/4885
US-20130289074-A1 NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS GPR119, GPR55, GPR52 TAS2R14 1225/4885POLB 4765/4885TDP1 4402/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.